Welcome to Actavis plc, the powerful combination of Actavis, Inc. and Warner Chilcott plc. As a result of this historic combination, we have transformed our company into a premier specialty pharmaceutical leader, uniquely positioned to meet the healthcare needs of patients around the world — particularly as a leader in Women’s Health.
Today, we provide trusted generic, branded generic and specialty pharmaceutical products in more than 60 countries, with the potential to reach more than 5 billion of the world’s consumers. And we are aggressively building a leading position in providing biosimilar versions of biopharmaceutical products in the coming years.
Through our combination with Warner Chilcott, we have accelerated Actavis Specialty Brands’ evolution into a global competitor and a key growth driver for the new company.
The acquisition more than doubles the size of our marketed Specialty Brands portfolio and delivers an industry leading pipeline with more than 25 products in various stages of development.
Within our Women’s Health segment, we expand our pipeline with the addition of seven new development programs encompassing three near-term launches and 12 products in late-stage development.
Additionally, the combination bolsters our Urology business, establishes a platform for continued expansion into the Gastroenterology and Dermatology therapeutic categories and provides the opportunity to introduce a broader portfolio of new products in Actavis’ expanded global footprint.
When combined with the global commercial presence of Actavis Pharma and the industry-leading Actavis Global Operations team, our combined organization today has a diversified geographic footprint and is an industry leader in research and development, focused on building the strongest pipeline in the industry in order to bring the right products to the right markets across the globe.
As we move forward, we are committed to leveraging our strengthened portfolio of marketed products, our enhanced research and development capabilities and pipeline and our expanded manufacturing footprint to capture synergies and drive continued growth and value for all of our shareholders, customers and employees around the world.
I hope you share my excitement as we celebrate this significant achievement in creating a more successful Actavis.